67337-05-7 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
2-[(tert-butoxycarbonyl)amino]-3-(5-fluoro-1H-indol-3-yl)propanoic acid serves as a crucial building block in the synthesis of potential therapeutic compounds. Its unique structure and functional groups make it a valuable tool for developing new drugs that can effectively target specific biological pathways, thereby enhancing the treatment of various diseases and conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-[(tert-butoxycarbonyl)amino]-3-(5-fluoro-1H-indol-3-yl)propanoic acid is employed as a versatile intermediate for the design and synthesis of novel drug candidates. Its Boc-protected amino group and fluorinated indole ring provide a solid foundation for the development of compounds with improved pharmacological properties, such as enhanced potency, selectivity, and bioavailability.
Used in Drug Discovery:
2-[(tert-butoxycarbonyl)amino]-3-(5-fluoro-1H-indol-3-yl)propanoic acid plays a significant role in drug discovery processes, where it is used to explore and identify new chemical entities with therapeutic potential. Its unique structural features and functional groups enable researchers to optimize the properties of drug candidates, leading to the development of more effective and safer medications.
Used in Biochemical Research:
In biochemical research, 2-[(tert-butoxycarbonyl)amino]-3-(5-fluoro-1H-indol-3-yl)propanoic acid is utilized as a probe to study the interactions between biological molecules and potential drug targets. Its structural characteristics allow researchers to gain insights into the mechanisms of action of various biological pathways, facilitating the discovery of new therapeutic targets and the design of targeted drug therapies.
Overall, 2-[(tert-butoxycarbonyl)amino]-3-(5-fluoro-1H-indol-3-yl)propanoic acid is a versatile and valuable compound in the fields of pharmaceutical research, drug development, medicinal chemistry, drug discovery, and biochemical research, owing to its unique structure and functional groups that enable the development of innovative therapeutic agents and the advancement of our understanding of biological pathways.
Check Digit Verification of cas no
The CAS Registry Mumber 67337-05-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,7,3,3 and 7 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 67337-05:
(7*6)+(6*7)+(5*3)+(4*3)+(3*7)+(2*0)+(1*5)=137
137 % 10 = 7
So 67337-05-7 is a valid CAS Registry Number.
67337-05-7Relevant articles and documents
A class of DL-tryptophan compounds, preparation method and applications thereof
-
Paragraph 0058-0061; 0062-0064, (2020/06/17)
The invention provides a DL-tryptophan compound represented by a general formula I or a pharmaceutically acceptable salt thereof, a preparation method and applications thereof, especially applicationsin preparation of RANKL inhibitors. According to the DL-tryptophan compound or the pharmaceutically acceptable salt thereof, an OPG-RANKL-RANK signal system can be intervened by inhibiting the interaction of RANKL-RANK, and the activity of RANKL in osteoclast precursor cells is regulated and controlled, so that formation of osteoclasts is inhibited, and bone resorption is reduced; and the DL-tryptophan compound or the pharmaceutically acceptable salt thereof is expected to play a role in preventing and treating bone metabolic diseases, and brings good news to bone metabolic disease patients.
Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL) - Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization
Jiang, Min,Peng, Lei,Yang, Kai,Wang, Tianqi,Yan, Xueming,Jiang, Tao,Xu, Jianrong,Qi, Jin,Zhou, Hanbing,Qian, Niandong,Zhou, Qi,Chen, Bo,Xu, Xing,Deng, Lianfu,Yang, Chunhao
supporting information, p. 5370 - 5381 (2019/06/24)
Targeting RANKL/RANK offers the possibility of developing novel therapeutic approaches to treat bone metabolic diseases. Multiple efforts have been made to inhibit RANKL. For example, marketed monoclonal antibody drug Denosumab could inhibit the maturation of osteoclasts by binding to RANKL. This study is an original approach aimed at discovering small-molecule inhibitors impeding RANKL/RANK protein interaction. We identified compound 34 as a potent and selective RANKL/RANK inhibitor by performing structure-based virtual screening and hit optimization. Disruption of the RANKL/RANK interaction by 34 effectively inhibits RANKL-induced osteoclastogenesis and bone resorption. The expression of osteoclast marker genes was also suppressed by treatment of 34. Furthermore, 34 markedly blocked the NFATc1/c-fos pathway. Thus, our current work demonstrates that the chemical tractability of the difficult PPI (RANKL/RANK) target by a small-molecule compound 34 offers a potential lead compound to facilitate the development of new medications for bone-related diseases.
